SCHEMBL3430972

SCHEMBL3430972

CC(C)CCN1CCCC1=O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.66
LMNA P02545 4/20 0.53
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
PKM P14618 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
BRD4 O60885 1/20 0.45
BRD2 P25440 1/20 0.45
TSHR P16473 3/20 0.44
CHRM2 P08172 3/20 0.42
CHRM5 P08912 3/20 0.42
CHRM1 P11229 3/20 0.42
CHRM3 P20309 3/20 0.42
CYP2D6 P10635 2/20 0.42
ALDH1A1 P00352 2/20 0.42
APEX1 P27695 2/20 0.42
PMP22 Q01453 2/20 0.42
ALOX12 P18054 1/20 0.42
NFKB1 P19838 1/20 0.42
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12197894 0.94 PIK3CD (0.58) PIK3CDLMNAKMT2AMEN1PKM
SCHEMBL104477 0.89 PIK3CD (0.61) PIK3CDLMNAKMT2AMEN1PKM
SCHEMBL7649491 0.86 PIK3CD (0.58) PIK3CDLMNAKMT2AMEN1PKM
SCHEMBL4327116 0.85 PIK3CD (0.58) PIK3CDLMNAKMT2AMEN1PKM
SCHEMBL5502986 0.85 PIK3CD (0.58) PIK3CDLMNAKMT2AMEN1PKM
SCHEMBL20886713 0.85 PIK3CD (0.56) PIK3CDLMNAKMT2AMEN1PKM
SCHEMBL19134337 0.85 PIK3CD (0.56) PIK3CDLMNAKMT2AMEN1PKM
SCHEMBL21207378 0.83 PIK3CD (0.55) PIK3CDLMNAKMT2AMEN1PKM
SCHEMBL5069393 0.83 PIK3CD (0.55) PIK3CDLMNAKMT2AMEN1PKM
SCHEMBL22600522 0.82 PIK3CD (0.53) PIK3CDLMNAKMT2AMEN1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240400784-A1 Method for Screening Solvent for Extracting Polyvinyl Chloride, Method for Recycling Waste, Recycled Polyvinyl Chloride, and Composition LG CHEM, LTD. (KR) 2024-12-05 US claimed
US-20240392094-A1 Method for Screening Solvent for Polyvinyl Chloride Extraction, Recycling Method for Waste Material, and Recycled Polyvinyl Chloride and Composition LG CHEM, LTD. (KR) 2024-11-28 US claimed
CN-117897440-A Method for screening solvent for extraction of polyvinyl chloride, method for recycling waste material, recycled polyvinyl chloride and composition 株式会社LG化学 2024-04-16 CN claimed
CN-117897439-A Method for screening solvent for extraction of polyvinyl chloride, method for recovering waste material, and recovered polyvinyl chloride and composition 株式会社LG化学 2024-04-16 CN claimed
WO-2023033601-A1 METHOD FOR SCREENING SOLVENT FOR POLYVINYL CHLORIDE EXTRACTION, RECYCLING METHOD FOR WASTE MATERIAL, AND RECYCLED POLYVINYL CHLORIDE AND COMPOSITION 주식회사 엘지화학 2023-03-09 WO claimed
WO-2023033605-A1 METHOD FOR SCREENING SOLVENT FOR EXTRACTING POLYVINYL CHLORIDE, METHOD FOR RECYCLING WASTE, RECYCLED POLYVINYL CHLORIDE, AND COMPOSITION 주식회사 엘지화학 2023-03-09 WO claimed
US-12532886-B2 Method of killing microbes using C3-C5 n-alkyl-gamma-butyrolactams and antimicrobial compositions containing same VIROX TECHNOLOGIES INC. (CA) 2026-01-27 US disclosed
US-20240423937-A1 METHODS OF TREATING PAIN AND USES THEREOF UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2024-12-26 US disclosed
US-20240400784-A1 Method for Screening Solvent for Extracting Polyvinyl Chloride, Method for Recycling Waste, Recycled Polyvinyl Chloride, and Composition LG CHEM, LTD. (KR) 2024-12-05 US disclosed
US-20240392094-A1 Method for Screening Solvent for Polyvinyl Chloride Extraction, Recycling Method for Waste Material, and Recycled Polyvinyl Chloride and Composition LG CHEM, LTD. (KR) 2024-11-28 US disclosed
US-12053540-B2 Antimicrobial compositions containing solvents including a C3-C5 N-alkyl-gamma-butyrolactam VIROX TECHNOLOGIES INC. (CA) 2024-08-06 US disclosed
US-12052990-B2 C3-C5 n-alkyl-gamma-butyrolactam containing antimicrobial compositions and methods of using same VIROX TECHNOLOGIES INC. (CA) 2024-08-06 US disclosed
US-20240156765-A1 METHODS OF NEUROPROTECTION AND USES THEREOF UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION 2024-05-16 US disclosed
US-8003660-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-08-23 US disclosed
US-20110183952-A1 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-28 US disclosed
US-20090263405-A1 CpG OLIGONUCLEOTIDE PRODRUGS, COMPOSITIONS THEREOF AND ASSOCIATED THERAPEUTIC METHODS GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY (US) 2009-10-22 US disclosed
US-7402606-B2 Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss SMITHKLINE BEECHAM CORPORATION (US) 2008-07-22 US disclosed
US-7393873-B2 Arylsulfonamide derivatives MERCK & CO., INC. (US) 2008-07-01 US disclosed
US-7320986-B2 Fused tri and tetra-cyclic pyrazole kinase inhibitors ABBOTT LABORTORIES (US) 2008-01-22 US disclosed
WO-2007100664-A2 MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12053540-B2 Antimicrobial compositions containing solvents including a C3-C5 N-alkyl-gamma-butyrolactam EBP, C5, CPS1 PIK3CD 816/4885LMNA 1690/4885KMT2A 4289/4885
US-20110183952-A1 NEW CHEMICAL COMPOUNDS MKI67, CCNA1, CCNT1 PIK3CD 3320/4885LMNA 302/4885KMT2A 3579/4885
US-12532886-B2 Method of killing microbes using C3-C5 n-alkyl-gamma-butyrolactams and antimicrobial compositions containing same C5, C9, C1S PIK3CD 1644/4885LMNA 426/4885KMT2A 4487/4885
US-20090263405-A1 CpG OLIGONUCLEOTIDE PRODRUGS, COMPOSITIONS THEREOF AND ASSOCIATED THERAPEUTIC METHODS TYMP, DCTD, TET1 PIK3CD 128/4885LMNA 4456/4885KMT2A 2152/4885
US-20240423937-A1 METHODS OF TREATING PAIN AND USES THEREOF ACHE, PDE6G, PTGES3 PIK3CD 4791/4885LMNA 2715/4885KMT2A 2542/4885
US-20240156765-A1 METHODS OF NEUROPROTECTION AND USES THEREOF NLN, BDNF, GAP43 PIK3CD 4631/4885LMNA 398/4885KMT2A 3586/4885
US-12052990-B2 C3-C5 n-alkyl-gamma-butyrolactam containing antimicrobial compositions and methods of using same C5, C1S, C9 PIK3CD 575/4885LMNA 1147/4885KMT2A 4078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.